There have been many recent developments in the pharmacological management of
alcohol withdrawal and alcohol dependence. Although previous treatments had included …

Addiction pharmacotherapy aims to prevent drug abstinence symptoms, reduce drug craving
and relapse, and normalize physiologic functions disrupted by chronic use of the drug …

ABSTRACT Introduction: Alcohol Use Disorders (AUD) is a leading cause of mortality and
morbidity worldwide. At present disulfiram, naltrexone and acamprosate are approved for …

During the past decade, renewed interest in medications to prevent relapse in alcoholics
has yielded a number of promising candidates. Although two of these medications …

Harmful alcohol use is a risk factor in more than 60 diseases and injuries resulting in
approximately 2.5 million deaths per year worldwide. In the United States (US) and Europe …

Aims Although debates over the efficacy of oral naltrexone and acamprosate in treating
alcohol use disorders tend to focus on their global efficacy relative to placebo or their …

Introduction: Alcohol use disorders are common, but only a small minority of patients receive
adequate treatment. Cognitive-behavioural therapies, motivational enhancement …

Abstract Background and Aims Pharmacologically controlled drinking in the treatment of
alcohol dependence or alcohol use disorders (AUDs) is an emerging concept. Our objective …

Patients who suffer from alcohol use disorders (AUDs) usually go through various socio-
behavioral and pathophysiological changes that take place in the brain and other organs …

Background: Renewed interest in medications to prevent relapse in alcoholics (ie,
antidipsotropics) resulted in approval by the Food and Drug Administration of naltrexone to …